Skip to Main Content

Paper Details

Facing the CDK4/6i resistance dilemma in patients with breast cancer, exploration of the resistance mechanism and possible reverse strategy: A narrative review.
Medicine (Baltimore)
0
2022
Breast cancer, CDK4, CDK4/6i, HER2, HR, HR+, breast cancer, cyclin-, cyclin-dependent kinase 4 and 6, growth factor receptor 2, hormone receptor, human, human epidermal, malignancy, metastatic breast cancer, patients, women
Author NameAffiliation
Jiayi WuZhejiang Chinese Medical University
Wei WangWenzhou Medical University
Wei WangWenzhou Medical University
Xiying ShaoZhejiang Cancer Hospital
Guang LinWenzhou Medical University
Guang LinWenzhou Medical University
Xiaojia WangZhejiang Cancer Hospital
  • 1 - 7

Datasets

Release 1.2